In serum, compound 23 and compound 30 are in equilibrium with their metabolites, which also displayed strong FASN activity inhibition (S1 Fig), in particular compound 30 (83% of FASN activity inhibition in SKBr3 human breast cancer cells). The gene discussed is FASN; the disease is breast carcinoma.